Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Walter E. Washington Convention Center

Jun 14, 2015 2:30 PM - Jun 18, 2015 6:45 PM

801 Mount Vernon Place, NW, , Washington, DC 20001-3614 , USA

DIA 2015 51st Annual Meeting: Develop. Innovate. Advance.

Full conference and one-day registrants will have access to presentation PDFs through Friday, December 18, 2015 <A href="http://www.diaglobal.org/Flagship-Meetings/DIA-Annual-Meeting/Meeting-Program/ePac-Presentations-Access.aspx">Review Presentations </A>

Clinical Quality by Design: From Theory to Practice

Session Chair(s)

Ann  Meeker-O'Connell, MS

Ann Meeker-O'Connell, MS

Director, Office of Clinical Policy, Office of Clinical Policy and Programs, OC

FDA, United States

QbD emphasizes building quality into a process from the beginning and has been successfully applied in the manufacturing arena. Applied in clinical development, QbD prospectively examines a trial's objectives and identifies the factors that are critical to meeting these objectives. Understanding these “critical to quality” aspects is essential to subsequently identifying and managing important and likely risks to trial quality. To support organizations seeking to implement QbD, a Clinical Trials Transformation Initiative (CTTI) project team is currently developing a portfolio of learning and operational tools. In addition, we will review these tools and highlight effective strategies that may aid in adoption of a QbD approach. This session will also discuss how pragmatic protocol design drawing on data standards and simulations may augment trial design and examine ways of leveraging insights from health care providers and payers to inform and improve protocol design.

Learning Objective : Describe strategies for implementing clinical quality by design (QbD) to build quality into the design and operations of clinical trials; Review tools and case studies from by the CTTI QbD project team to suport implementation of clinical QbD; Examine ways of leveraging insights from health care providers and payers to inform and improve protocol design.

Speaker(s)

Coleen  Glessner, MBA

From Principles to Practice: An Industry Perspective

Coleen Glessner, MBA

Alexion Pharmaceuticals, United States

Senior Vice President, Chief Quality Officer

James  Streeter

Towards More Effective Protocols and Safer Trials Starting With Standards and Simulating Designs

James Streeter

Oracle Health Sciences, United States

Global Vice President, Life Sciences Product Strategy

Jean M. Mulinde, MD

FDA Point of View

Jean M. Mulinde, MD

FDA, United States

Associate Director, Division of Clinical Compliance Evaluation, OSI

Have an account?

Ways to register

Registration override should work.

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.